AR119698A2 - Compuesto amida n-urea sustituida derivado de aminoácido - Google Patents

Compuesto amida n-urea sustituida derivado de aminoácido

Info

Publication number
AR119698A2
AR119698A2 ARP200100544A ARP200100544A AR119698A2 AR 119698 A2 AR119698 A2 AR 119698A2 AR P200100544 A ARP200100544 A AR P200100544A AR P200100544 A ARP200100544 A AR P200100544A AR 119698 A2 AR119698 A2 AR 119698A2
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
hydrogen
aryl
cycloalkyl
Prior art date
Application number
ARP200100544A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47116500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR119698(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR119698A2 publication Critical patent/AR119698A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/42—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43—Y being a hetero atom
    • C07C323/44—X or Y being nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)

Abstract

Compuestos amida N-urea sustituida derivados de aminoácidos representados por la fórmula (1). Reivindicación 1: Un compuesto amida N-urea sustituida derivado de aminoácido caracterizado porque está representado por la fórmula (1), sus enantiómeros, diastereoisómeros, tautómeros, hidratos, solvatos o sales farmacéuticamente aceptables del mismo, en donde: a es 1 y b es 0; a es 0 y b es 1; a es 1 y b es 1; R¹ es alquilo C₁₋₈ opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, heterociclo opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, arilo C₆₋₁₀ opcionalmente sustituido, cicloalquenilo C₃₋₈ opcionalmente sustituido, -NR¹¹R¹² o -OR¹³; R² es alquilo C₁₋₈ opcionalmente sustituido o arilo C₆₋₁₀ opcionalmente sustituido; R³ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido, halógeno, -COOR¹⁵, -OR¹³, -NR¹¹R¹², NO₂, heterociclo opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, arilo C₆₋₁₀ opcionalmente sustituido o cicloalquenilo C₃₋₈ opcionalmente sustituido; R⁴ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido, halógeno, -COOR¹⁵, -OR¹³, -NR¹¹R¹², NO₂, heterociclo opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, arilo C₆₋₁₀ opcionalmente sustituido o cicloalquenilo C₃₋₈ opcionalmente sustituido; R⁵ es halógeno, -CF₃ o -S(O)ₙR¹⁴; n es 0, 1 ó 2; R⁶ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido, halógeno, -COOR¹⁵, -OR¹³, -NR¹¹R¹², NO₂, heterociclo opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, arilo C₆₋₁₀ opcionalmente sustituido o cicloalquenilo C₃₋₈ opcionalmente sustituido; R⁷ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido, halógeno, -COOR¹⁵, -OR¹³, -NR¹¹R¹², NO₂, heterociclo opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, arilo C₆₋₁₀ opcionalmente sustituido o cicloalquenilo C₃₋₈ opcionalmente sustituido; R⁸ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido o arilo C₆₋₁₀ opcionalmente sustituido; R⁹ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido o arilo C₆₋₁₀ opcionalmente sustituido; R¹⁰ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido o arilo C₆₋₁₀ opcionalmente sustituido; R⁹ᵃ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido o arilo C₆₋₁₀ opcionalmente sustituido; R¹⁰ᵃ es hidrógeno, alquilo C₁₋₈ opcionalmente sustituido o arilo C₆₋₁₀ opcionalmente sustituido; R¹¹ es hidrógeno o alquilo C₁₋₈ opcionalmente sustituido; R¹² es hidrógeno o alquilo C₁₋₈ opcionalmente sustituido; R¹³ es hidrógeno o alquilo C₁₋₈ opcionalmente sustituido; R¹⁴ es hidrógeno, CF₃ o alquilo C₁₋₈ opcionalmente sustituido; R¹⁵ es hidrógeno o alquilo C₁₋₈ opcionalmente sustituido; con la condición de que: a). cuando a = 1 y b = 0 entonces: R⁹ no es bencilo opcionalmente sustituido; y R¹¹ no es: un compuesto del grupo de fórmulas (2); y el compuesto de la fórmula (1) no es de las estructuras: del grupo de fórmulas (3); y b). cuando a = 0 y b = 1 entonces: R¹ es OR¹³; y el compuesto de la fórmula (1) no es de la estructura: de fórmula (4); y c). cuando a = 1 y b = 1 entonces: R¹¹ no es: un resto de fórmula (5).
ARP200100544A 2011-10-26 2020-02-27 Compuesto amida n-urea sustituida derivado de aminoácido AR119698A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161551772P 2011-10-26 2011-10-26

Publications (1)

Publication Number Publication Date
AR119698A2 true AR119698A2 (es) 2022-01-05

Family

ID=47116500

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP120104004A AR088535A1 (es) 2011-10-26 2012-10-25 Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1)
ARP200100544A AR119698A2 (es) 2011-10-26 2020-02-27 Compuesto amida n-urea sustituida derivado de aminoácido

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP120104004A AR088535A1 (es) 2011-10-26 2012-10-25 Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1)

Country Status (32)

Country Link
US (9) US8658803B2 (es)
EP (2) EP2770989B1 (es)
JP (3) JP5982001B2 (es)
KR (1) KR102051687B1 (es)
CN (2) CN104114164B (es)
AR (2) AR088535A1 (es)
AU (3) AU2012329098B2 (es)
BR (2) BR122019025505B1 (es)
CA (1) CA2853648C (es)
CL (1) CL2014001080A1 (es)
CO (1) CO6960509A2 (es)
CY (1) CY1121604T1 (es)
DK (1) DK2770989T3 (es)
ES (2) ES2820714T3 (es)
HR (1) HRP20181934T1 (es)
HU (1) HUE040145T2 (es)
IL (3) IL232204B (es)
IN (1) IN2014DN03424A (es)
LT (1) LT2770989T (es)
MX (2) MX357737B (es)
MY (1) MY172013A (es)
PH (2) PH12019500171B1 (es)
PL (1) PL2770989T3 (es)
PT (1) PT2770989T (es)
RS (1) RS58111B1 (es)
RU (2) RU2744577C2 (es)
SG (2) SG11201401818RA (es)
SI (1) SI2770989T1 (es)
TW (1) TWI631099B (es)
UA (1) UA115043C2 (es)
WO (1) WO2013062947A1 (es)
ZA (1) ZA201403222B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
PT2770989T (pt) * 2011-10-26 2018-12-04 Allergan Inc Derivados de amida de aminoácidos substituídos por n-ureia como moduladores de recetor tipo-1 do recetor de péptidos formil (fprl-1)
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
CA2899804A1 (en) * 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
RU2663911C2 (ru) * 2013-03-06 2018-08-13 Аллерган, Инк. Применение агонистов формилпептидного рецептора 2 для лечения воспалительных заболеваний глаз
AU2014290618B2 (en) * 2013-07-16 2018-04-05 Allergan, Inc. Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
TWI537251B (zh) 2013-10-09 2016-06-11 長庚大學 Ｆｐｒ１拮抗劑的衍生物及其用途
AU2014352922B2 (en) * 2013-11-21 2018-06-07 Allergan, Inc. Phenylcarbamate derivatives as formyl peptide receptor modulators
NZ752095A (en) 2013-11-28 2022-07-01 Kyorin Seiyaku Kk Urea derivative or pharmacologically acceptable salt thereof
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
US10301269B2 (en) 2014-05-21 2019-05-28 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators
US10858314B2 (en) * 2015-05-27 2020-12-08 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US10525058B2 (en) * 2015-05-27 2020-01-07 Kyorin Pharmaceutical Co., Ltd Urea derivative or pharmacologically acceptable salt thereof
TW201718473A (zh) * 2015-08-05 2017-06-01 歐樂根公司 作為甲醯肽受體１（ｆｐｒ１）選擇性促效劑之苯基脲類似物
WO2017172761A1 (en) 2016-03-28 2017-10-05 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
CA3020316A1 (en) * 2016-04-12 2017-10-19 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
CA3130536A1 (en) * 2016-10-06 2018-04-12 Daiichi Sankyo Company, Limited Urea derivative
JP2020015664A (ja) * 2016-11-21 2020-01-30 宇部興産株式会社 含窒素多環式ヘテロ環誘導体
US10608869B2 (en) * 2017-03-20 2020-03-31 Nicira, Inc. Handling control-plane connectivity loss in virtualized computing environments
SG11202008504SA (en) 2018-03-05 2020-10-29 Bristol Myers Squibb Co Phenylpyrrolidinone formyl peptide 2 receptor agonists
EP4234014A1 (en) * 2022-02-28 2023-08-30 Insusense ApS Amino acid based carbamates and/or ureas for the treatment of sortilin dependent diseases
WO2025144935A1 (en) * 2023-12-26 2025-07-03 Development Center For Biotechnology Heterocycle compounds as formyl peptide receptor modulators
WO2025233915A1 (en) 2024-05-10 2025-11-13 Allgenesis Biotherapeutics Inc. Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) * 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
JP3387948B2 (ja) 1992-12-04 2003-03-17 富山化学工業株式会社 新規なフェニルアラニン誘導体またはその塩
AU667995B2 (en) * 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
WO1995012612A1 (en) * 1993-11-05 1995-05-11 Warner-Lambert Company Substituted di- and tripeptide inhibitors of protein:farnesyl transferase
JPH11171896A (ja) * 1995-09-19 1999-06-29 Kirin Brewery Co Ltd 新規ペプチド化合物およびその医薬組成物
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
AU4572999A (en) 1998-06-18 2000-01-05 Sepracor, Inc. Tetrapeptides, analogs and peptidomimetics which bind selectively mammalian opioid receptors
US6243689B1 (en) 1998-12-29 2001-06-05 Robert G. Norton System and method for authorizing electronic funds transfer at a point of sale
AU6909300A (en) 1999-08-20 2001-03-19 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
AU2002255485A1 (en) * 2001-01-19 2002-09-12 The Scripps Research Institute Hiv/fiv protease inhibitors
AU2002352245B2 (en) * 2001-12-12 2008-10-16 Wilex Ag Selective arylguanidine peptides as urokinase inhibitors
EP1537075B1 (en) 2002-09-05 2009-07-01 Neurosearch A/S Diarylurea derivatives and their use as chloride channel blockers
AU2003259007A1 (en) * 2002-10-31 2004-05-25 Amersham Biosciences Ab Use of urea variants as affinity ligands
WO2004041850A1 (ja) 2002-11-07 2004-05-21 Takeda Pharmaceutical Company Limited 新規なｆｐｒｌ１リガンドおよびその用途
KR100527361B1 (ko) * 2003-04-01 2005-11-09 주식회사 프로메디텍 데포르밀라제 저해제, 이의 제조방법, 및 이를 포함하는조성물
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
EP1692502A2 (en) * 2003-11-07 2006-08-23 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
CN1894580A (zh) * 2003-11-07 2007-01-10 阿卡蒂亚药品公司 脂氧素受体fprl1作为一种用于鉴定能有效治疗疼痛和炎症化合物的工具
EP1695961A4 (en) 2003-12-17 2007-10-24 Takeda Pharmaceutical UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE
GB0417802D0 (en) 2004-08-10 2004-09-15 Novartis Ag Organic compounds
US20070287716A1 (en) 2004-10-28 2007-12-13 Hu Essa H Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors
US7678913B2 (en) 2004-12-07 2010-03-16 Portola Pharmaceuticals, Inc. Ureas as factor Xa inhibitors
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
EP2492278A1 (en) 2006-09-18 2012-08-29 Compugen Ltd. Antibodies against an agonist of G-protein coupled receptors and its use indiagnosis and therapy
AR065093A1 (es) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos
KR20090121832A (ko) 2008-05-23 2009-11-26 인제대학교 산학협력단 2-(2-히드록시벤조일)히드라진카르복시아미드 유도체 또는이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를유효 성분으로 함유하는 선택적 면역 억제용 약학적 조성물
US20100035932A1 (en) 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
AR074874A1 (es) * 2008-12-23 2011-02-16 Biosource Pharm Inc Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.
CA2803920A1 (en) 2010-06-24 2011-12-29 Richard Beard Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
CA2819457A1 (en) 2010-12-03 2012-06-07 Allergan, Inc. Pharmaceutical compositions comprising 3,4-dihydroisoquinolin-2(1h)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
WO2012109544A1 (en) 2011-02-11 2012-08-16 Allergan, Inc. Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US20120329873A1 (en) 2011-06-17 2012-12-27 Li yong-xin D-serine for the treatment of visual system disorders
GB2494851A (en) * 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
CA2841983A1 (en) 2011-07-11 2013-01-17 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators
PT2770989T (pt) * 2011-10-26 2018-12-04 Allergan Inc Derivados de amida de aminoácidos substituídos por n-ureia como moduladores de recetor tipo-1 do recetor de péptidos formil (fprl-1)
US8541577B2 (en) 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8492556B2 (en) 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
CA2864893A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators
WO2013158597A1 (en) 2012-04-16 2013-10-24 Allergan, Inc. (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators
CA2899804A1 (en) * 2013-03-06 2014-09-12 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
RU2663911C2 (ru) 2013-03-06 2018-08-13 Аллерган, Инк. Применение агонистов формилпептидного рецептора 2 для лечения воспалительных заболеваний глаз
AU2014290618B2 (en) 2013-07-16 2018-04-05 Allergan, Inc. Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
US20150080466A1 (en) 2013-09-19 2015-03-19 Allergan, Inc. Diphenyl urea derivatives as formyl peptide receptor modulators
JP6172288B2 (ja) 2013-10-24 2017-08-02 トヨタ自動車株式会社 ナトリウム電池用正極活物質及びナトリウム電池
AU2014352922B2 (en) 2013-11-21 2018-06-07 Allergan, Inc. Phenylcarbamate derivatives as formyl peptide receptor modulators
US10301269B2 (en) 2014-05-21 2019-05-28 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators

Also Published As

Publication number Publication date
PH12019500171B1 (en) 2022-08-12
BR122019025505B1 (pt) 2022-02-22
IL232204A0 (en) 2014-06-30
DK2770989T3 (en) 2018-12-17
BR112014010042B1 (pt) 2022-03-03
IL267659B (en) 2021-10-31
EP2770989A1 (en) 2014-09-03
EP3078656A1 (en) 2016-10-12
US20150148395A1 (en) 2015-05-28
AR088535A1 (es) 2014-06-18
ES2708997T3 (es) 2019-04-12
RU2017129434A (ru) 2019-02-04
US20170119737A1 (en) 2017-05-04
CL2014001080A1 (es) 2014-11-14
US8993780B2 (en) 2015-03-31
JP2016216497A (ja) 2016-12-22
SG11201401818RA (en) 2014-05-29
PL2770989T3 (pl) 2019-01-31
IL232204B (en) 2018-12-31
US10172832B2 (en) 2019-01-08
EP3078656B1 (en) 2020-07-01
PH12019500171A1 (en) 2020-06-15
PH12014500928A1 (en) 2014-06-23
US20190343804A1 (en) 2019-11-14
CO6960509A2 (es) 2014-05-30
MX376348B (es) 2025-03-07
US20220202777A1 (en) 2022-06-30
UA115043C2 (uk) 2017-09-11
IL256555A (en) 2018-02-28
AU2019264555A1 (en) 2019-12-05
WO2013062947A1 (en) 2013-05-02
JP6496689B2 (ja) 2019-04-03
AU2019264555B2 (en) 2020-12-17
CA2853648C (en) 2023-01-24
JP2014534216A (ja) 2014-12-18
CN104114164B (zh) 2016-11-16
MY172013A (en) 2019-11-12
BR112014010042A8 (pt) 2017-06-20
AU2017251683C1 (en) 2019-11-14
CA2853648A1 (en) 2013-05-02
US9351948B2 (en) 2016-05-31
AU2017251683B2 (en) 2019-08-15
KR102051687B1 (ko) 2019-12-17
US9579307B2 (en) 2017-02-28
US9974772B2 (en) 2018-05-22
SG10201903266YA (en) 2019-05-30
SI2770989T1 (sl) 2018-12-31
CN106518742B (zh) 2020-01-21
US20240285584A1 (en) 2024-08-29
RS58111B1 (sr) 2019-02-28
JP2019089849A (ja) 2019-06-13
HUE040145T2 (hu) 2019-02-28
BR112014010042A2 (pt) 2017-06-13
PH12014500928B1 (en) 2021-03-26
RU2014120013A (ru) 2015-12-10
IL256555B (en) 2020-07-30
CN104114164A (zh) 2014-10-22
EP2770989B1 (en) 2018-09-05
RU2629205C2 (ru) 2017-08-25
US20160235711A1 (en) 2016-08-18
RU2017129434A3 (es) 2020-10-09
ES2820714T3 (es) 2021-04-22
US10993931B2 (en) 2021-05-04
MX2014005047A (es) 2015-09-04
US8658803B2 (en) 2014-02-25
HK1199622A1 (en) 2015-07-10
CY1121604T1 (el) 2020-05-29
US20140094614A1 (en) 2014-04-03
JP6804580B2 (ja) 2020-12-23
PT2770989T (pt) 2018-12-04
US20180228772A1 (en) 2018-08-16
LT2770989T (lt) 2018-12-10
HRP20181934T1 (hr) 2019-01-25
NZ624635A (en) 2017-01-27
AU2012329098B2 (en) 2017-08-03
CN106518742A (zh) 2017-03-22
ZA201403222B (en) 2015-07-29
TWI631099B (zh) 2018-08-01
IN2014DN03424A (es) 2015-06-05
RU2744577C2 (ru) 2021-03-11
TW201331168A (zh) 2013-08-01
JP5982001B2 (ja) 2016-08-31
AU2012329098A1 (en) 2014-05-22
AU2017251683A1 (en) 2017-11-09
KR20140111646A (ko) 2014-09-19
IL267659A (en) 2019-08-29
MX357737B (es) 2018-07-23
US20130109866A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
AR088535A1 (es) Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1)
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
CU20080165A7 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR079164A1 (es) Derivados heterociclicos de indol, composiciones farmaceuticas que los comprenden y uso de los mismos para la profilaxis o tratamiento de enfermedades alergicas, inflamatorias y/o autoinmunes.
AR087711A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y uso de los mismos para el tratamiento de trastornos neurodegenerativos
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR108838A1 (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AR087757A1 (es) Inhibidores selectivos y reversibles de la proteasa especifica de ubiquitina 7, sus composiciones farmaceuticas y sus aplicaciones terapeuticas
AR103561A1 (es) Fenilpiridinas herbicidas
AR106798A1 (es) Inhibidores pirazol de acc y usos de los mismos
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR086538A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR072227A1 (es) Derivados de triazinona sustituidos
AR105893A1 (es) Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
AR092306A1 (es) Antibacterianos de fenicol
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1

Legal Events

Date Code Title Description
FB Suspension of granting procedure